Issue Date | Title | Author(s) | Relation | scopus | WOS | Fulltext/Archive link |
2011 | A humanized immunoenzyme with enhanced activity for glucuronide prodrug activation in the tumor microenvironment. | Chen, KC; Wu, SY; Leu, YL; Prijovich, ZM; Chen, BM; Wang, HE; Cheng, TL; Roffler, SR | Bioconjugate chemistry 22(5), 938-948 | | | |
2009 | Antiangiogenesis targeting tumor microenvironment synergizes glucuronide prodrug antitumor activity. | Juan, TY; Roffler, SR; Hou, HS; Huang, SM; Chen, KC; Leu, YL; Prijovich, ZM; Yu, CP; Wu, CC; Sun, GH; Cha, TL | CLINICAL CANCER RESEARCH 15(14), 4600-4611 | | | |
2008 | Directed evolution of a lysosomal enzyme with enhanced activity at neutral pH by mammalian cell-surface display. | Chen, KC; Wu, CH; Chang, CY; Lu, WC; Tseng, Q; Prijovich, ZM; Schechinger, W; Liaw, YC ; Leu, YL; Roffler, SR | Chemistry & Biology 15(12), 1277-1286 | | | |
2012 | ECSTASY, an adjustable membrane-tethered/soluble protein expression system for the directed evolution of mammalian proteins. | Chen, CP; Hsieh, YT; Prijovich, ZM; Chuang, HY; Chen, KC; Lu, WC; Tseng, Q; Leu, YL; Cheng, TL; Roffler, SR | PROTEIN ENGINEERING DESIGN & SELECTION 25(7), 367-375 | | | |
2011 | Enhancement of CPT-11 antitumor activity by adenovirus-mediated expression of beta-glucuronidase in tumors. | Huang, PT; Chen, KC; Prijovich, ZM; Cheng, TL; Leu, YL; Roffler, SR | Cancer gene therapy 18(6), 381-389 | | | |
2009 | Local enzymatic hydrolysis of an endogenously-generated metabolite can enhance CPT-11 anti-cancer efficacy | Prijovich, ZM; Chen, KC; Roffler, SR | Molecular Cancer Research 8(4), 940-946 | | | |
2016 | Synthesis and Antitumor Properties of BQC-Glucuronide, a Camptothecin Prodrug for Selective Tumor Activation. | Prijovich, ZM; Burnouf, PA; Chou, HC; Huang, PT; Chen, KC; Cheng, TL; Leu, YL; Roffler, SR | Molecular pharmaceutics 13(4), 1242-50 | | | |